N. Bourayou

发表

Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.

G. Hillerdal, M. Nicolson, Y. Summers, 2015, Lung cancer.

Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study

G. Hillerdal, A. Santoro, A. Favaretto, 2014 .

Experimental and theoretical study of the influence of salt on liquid phase equilibria for totally miscible organic compounds with water

N. Bourayou, A. Meniai, 2005 .

[Chemotherapy-induced cardiotoxicity in the elderly].

J. Gligorov, F. Selle, J. Lotz, 2008, Bulletin du cancer.

Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.

F. Mornex, N. Chouaki, K. Peignaux, 2013, Lung cancer.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

M. Goetz, M. Campone, J. Huober, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

P. Neven, G. Sledge, X. Pivot, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)

B. Monk, J. Sehouli, K. Moxley, 2020, Journal for ImmunoTherapy of Cancer.

Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.

F. Denis, R. Gervais, G. Robinet, 2013, Lung cancer.

Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design

G. Hillerdal, M. Nicolson, C. Visseren-Grul, 2013, Health and Quality of Life Outcomes.

236O_PRMONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer

M. Goetz, M. Campone, J. Huober, 2017 .

Abstract OT3-05-05: MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer

N. Harbeck, S. Johnston, M. Toi, 2018 .

Effect of calcium chloride on the liquid-liquid equilibria of the water-acetone system

N. Bourayou, A. Meniai, 2007 .

MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy

P. Neven, G. Sledge, X. Pivot, 2017 .

MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).

M. Goetz, A. Leo, M. Toi, 2015 .

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

U. Banerji, J. Powderly, N. Lakhani, 2024, ESMO open.